Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Definium Therapeutics, Inc. - Common Shares (NQ:DFTX)

21.71 +0.84 (+4.02%)
Streaming Delayed Price Updated: 11:34 AM EDT, May 21, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Definium Therapeutics, Inc. - Common Shares

News headline image
Definium Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference
From Definium Therapeutics, Inc.
Via Business Wire
News headline image
What to Know About This Fund’s New $22 Million Xenon Pharmaceuticals Buy Ahead of an FDA Filing ↗
Xenon Pharmaceuticals develops therapies for neurological disorders, with a pipeline targeting epilepsy and related conditions. 
Via The Motley Fool
News headline image
Dianthus Therapeutics Is Up 320% in a Year. One Major Investor Just Reduced Its Stake but Still Seems Bullish ↗
Specializing in monoclonal antibody therapies, this clinical-stage biotech targets severe autoimmune and inflammatory diseases. 
Via The Motley Fool
Topics Regulatory Compliance
Definium Therapeutics (NASDAQ:DFTX) Misses EPS but Pipeline Progress Steals the Spotlight ↗
Via Chartmill
News headline image
Definium Therapeutics Announces First Patient Dosed in Ascend, the Second Phase 3 Pivotal Study of DT120 ODT in Major Depressive Disorder
From Definium Therapeutics, Inc.
Via Business Wire
News headline image
Definium Therapeutics Announces New Employee Inducement Grants
From Definium Therapeutics, Inc.
Via Business Wire
News headline image
Definium (DFTX) Q1 2026 Earnings Transcript ↗
Definium (DFTX) Q1 2026 Earnings Transcript 
Via The Motley Fool
News headline image
Definium Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights
From Definium Therapeutics, Inc.
Via Business Wire
News headline image
Definium Therapeutics to Report First Quarter 2026 Financial Results on May 7, 2026
From Definium Therapeutics, Inc.
Via Business Wire
News headline image
These 3 Psychedelic Stocks Activated After Trump's Executive Order ↗
Via MarketBeat
Topics Government
News headline image
Definium Therapeutics Highlights DT120 ODT (Lysergide Tartrate) Clinical Advancements and Commercial Strategy at Investor and Analyst Day
From Definium Therapeutics, Inc.
Via Business Wire
News headline image
Definium Therapeutics Announces New Employee Inducement Grants
From Definium Therapeutics, Inc.
Via Business Wire
News headline image
Trump Just Fast-Tracked Psychedelic Treatments: 3 Under-the-Radar Stocks That Could Be About to Soar ↗
Trump is easing approval for psychedelic treatments for mental disorders. 
Via The Motley Fool
Topics Government
News headline image
Definium Therapeutics Applauds White House Executive Order to Accelerate Mental Health Innovation and Expand Access to Psychedelic Medical Treatments
From Definium Therapeutics, Inc.
Via Business Wire
News headline image
Definium Therapeutics to Participate at Upcoming Investor Conferences and Events
From Definium Therapeutics, Inc.
Via Business Wire
News headline image
New Definium Therapeutics Study Published in the Journal of Mood and Anxiety Disorders Reveals Increasing Prevalence and Burden of Generalized Anxiety Disorder in the United States
From Definium Therapeutics, Inc.
Via Business Wire
News headline image
Definium Therapeutics Announces New Employee Inducement Grants
From Definium Therapeutics, Inc.
Via Business Wire
News headline image
Definium Therapeutics to Host Investor and Analyst Day in New York on April 22, 2026
From Definium Therapeutics, Inc.
Via Business Wire
News headline image
This $6 Million Bet Adds a Brain Health Biotech to Portfolio Dominated by Clinical Stage Names ↗
This clinical-stage biopharma targets neurological and psychiatric disorders with a pipeline of novel therapeutics advancing through trials. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Definium Therapeutics Announces New Employee Inducement Grants
From Definium Therapeutics, Inc.
Via Business Wire
News headline image
Definium (DFTX) Q4 2025 Earnings Call Transcript ↗
Definium (DFTX) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Definium Therapeutics Reports Full-Year 2025 Financial Results and Business Updates
From Definium Therapeutics, Inc.
Via Business Wire
News headline image
Definium Therapeutics to Participate at Upcoming Investor Conferences
From Definium Therapeutics, Inc.
Via Business Wire
News headline image
Definium Therapeutics to Report Full Year 2025 Financial Results on February 26, 2026
From Definium Therapeutics, Inc.
Via Business Wire
News headline image
Definium Therapeutics Announces New Employee Inducement Grants
From Definium Therapeutics, Inc.
Via Business Wire
News headline image
Definium Therapeutics Appoints Roger Adsett to Board of Directors
From Definium Therapeutics, Inc.
Via Business Wire
News headline image
Definium Therapeutics Announces New Employee Inducement Grants
From Definium Therapeutics, Inc.
Via Business Wire
News headline image
Definium Therapeutics Introduces Rerouting Minds, an Educational Campaign Exploring the Potential of Pharmaceutical Lysergide (LSD) in Mental Health Care
From Definium Therapeutics, Inc.
Via Business Wire
News headline image
2026 Asset Growth: Why Federal Compliance Is the New Metric
ISSUED ON BEHALF OF DOSEOLOGY SCIENCES INC. 
From Equity Insider
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.